Goldman Sachs raised the firm’s price target on Halozyme (HALO) to $56 from $54 and keeps a Neutral rating on the shares. Halozyme announced a global non-exclusive collaboration and license agreement with Merus to use Halozyme’s Enhanze technology in the development of a subcutaneous formulation of petosemtamab, the analyst tells investors in a research note. While strategically positive, Goldman doesn’t expect the announcement to meaningfully move the stock.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Merus, Halozyme enter collaboration, license agreement for petosemtamab
- Halozyme Completes $1.5 Billion Convertible Notes Sale
- Halozyme: JNJ gets FDA approval for new indication of DARZALEX Faspro
- Halozyme Announces Pricing of $1.3 Billion in Notes
- Halozyme Extends Credit Facility and Increases Commitments